Benfluorex as a therapeutic option for insulin resistance in HIV lipodystrophy syndrome

HIV Clinical Trials

Volumn 5, Issue 2, 2004, Pages 86-90

  Poizot Martin, Isabelle ^a,b   Marimoutou, C ^a,b   Vion Dury, F ^a   Gregoire R ^a   Dinh, T ^a   Djemli, K ^a,d   Di Stefano, D ^c   Vague, Ph ^d   Gastaut, J A ^a,c  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Antiretroviral therapy associated metabolic disorders; Benfluorex; HIV infection; Insulin resistance; Lipodystrophy syndrome; Oral glucose tolerance test

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; BENFLUOREX; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; INSULIN; LACTIC ACID; LAMIVUDINE; LIPID; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG INDICATION; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PRESCRIPTION; PRIORITY JOURNAL; SUBCUTANEOUS FAT; THIGH; TREATMENT OUTCOME; TREATMENT PLANNING; VISCERA;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; ANTILIPEMIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENFLURAMINE; GLUCOSE TOLERANCE TEST; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 2542632658     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/4Y50-FGAG-PEYR-K25X     Document Type: Article

References (12)

1. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003;22:89-99.
2. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472-477.
3. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl 2):S85-90.
4. Roger P, Auclair J, Drain P. Addition of benfluorex to biguanide improves glycemic control in obese insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications. 1999;13:62-67.
5. Lo J C, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86:3480-3487.
6. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002;31(2):163-170.
7. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther. 2003;8(3):199-207.
8. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
9. Lafeuillade A, Hittinger G, Chadapaud S, et al. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-281.
10. Bianchi R, Bongers V, Bravenboer B, Erkelens DW. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care. 1993;16:557-559.
11. Del Prato S, Erkelens DW, Leutenegger M. Six months efficacy of benfluorex vs. placebo or metformin in dietfailed type 2 diabetic patients. Acta Diabetol. 2003;40:20-27.
12. Chaine B, Morand JJ, Folchetti G, Hesse S, Jean-Pastor MJ, Bonerandi JJ. Urticaria and anaphylactic shock from benfluorex. Two case reports. Ann Dermatol Venereol. 1998;125(3):202.